Bispidine Chelators for Radiopharmaceutical Applications with Lanthanide, Actinide, and Main Group Metal Ions

化学 镧系元素 螯合作用 配体(生物化学) 金属 水溶液中的金属离子 联吡啶 同核分子 三吡啶 锕系元素 衍生工具(金融) 密度泛函理论 离子 组合化学 无机化学 计算化学 结晶学 分子 有机化学 晶体结构 受体 生物化学 金融经济学 经济
作者
I. Kopp,Patrick Cieslik,Karl Anger,Thomas Josephy,Lucca Neupert,Gunasekaran Velmurugan,Michael Gast,Hubert Wadepohl,Santiago Andrés Brühlmann,Martin Walther,Klaus Kopka,Michael Bachmann,Holger Stephan,Manja Kubeil,Peter Comba
出处
期刊:Inorganic Chemistry [American Chemical Society]
卷期号:62 (50): 20754-20768 被引量:6
标识
DOI:10.1021/acs.inorgchem.3c02340
摘要

Octadentate and specifically nonadentate ligands with a bispidine scaffold (3,7-diazabicyclo[3.3.1]nonane) are known to be efficiently coordinated to a range of metal ions of interest in radiopharmaceutical chemistry and lead to exceedingly stable and inert complexes. Nonadentate bispidine L2 (with a tridentate bipyridine acetate appended to N3 and a picolinate at N7) has been shown before to be an ideal chelator for 111In3+, 177Lu3+, and 225Ac3+, nuclides of interest for diagnosis and therapy, and a proof-of-principle study with an SSTR2-specific octreotate has shown potential for theranostic applications. We now have extended these studies in two directions. First, we present ligand derivative L3, in which the bipyridine acetate is substituted with terpyridine, a softer donor for metal ions with a preference for more covalency. L3 did not fulfill the hopes because complexation is much less efficient. While for Bi3+ and Pb2+ the ligand is an excellent chelator with properties similar to those of L2, Lu3+ and La3+ show very slow and inefficient complexation with L3 in contrast to L2, and 225Ac3+ is not fully coordinated, even at an increased temperature (92% radiochemical yield at 80 °C, 60 min, [L3] = 10-4 M). These observations have led to a hypothesis for the complexation pathway that is in line with all of the experimental data and supported by a preliminary density functional theory analysis, which is important for the design of further optimized bispidine chelators. Second, the coordination chemistry of L2 has been extended to Bi3+, La3+, and Pb2+, including solid state and solution structural work, complex stabilities, radiolabeling, and radiostability studies. All complexes of this ligand (La3+, Ac3+, Lu3+, Bi3+, In3+, and Pb2+), including nuclides for targeted α therapy (TAT), single-photon emission computed tomography, and positron emission tomography, are formed efficiently under physiological conditions, i.e., suitable for the labeling of delicate biological vectors such as antibodies, and the complexes are very stable and inert. Importantly, for TAT with 225Ac, the daughter nuclides 213Bi and 209Pb also form stable complexes, and this is important for reducing damage to healthy tissue.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Kavin完成签到,获得积分10
刚刚
南南东完成签到,获得积分10
刚刚
刚刚
qinyingxin应助一汪采纳,获得10
1秒前
skr完成签到,获得积分10
1秒前
2秒前
Tigher发布了新的文献求助10
2秒前
科研通AI6.3应助zw0907采纳,获得10
3秒前
桐桐应助沙拉酱采纳,获得10
3秒前
科研通AI6.3应助健忘碧菡采纳,获得10
3秒前
玛卡巴卡完成签到 ,获得积分10
3秒前
4秒前
石榴完成签到,获得积分20
4秒前
hui发布了新的文献求助10
5秒前
冰柠檬完成签到,获得积分10
5秒前
6秒前
7秒前
Lucas应助kk采纳,获得10
7秒前
9秒前
无极微光应助甜栗栗子采纳,获得20
9秒前
桐炫完成签到,获得积分10
10秒前
10秒前
石榴发布了新的文献求助10
10秒前
科研通AI6.3应助Lorain采纳,获得10
11秒前
付榆峰发布了新的文献求助10
11秒前
orixero应助cardiomyocytes采纳,获得20
11秒前
丁峰发布了新的文献求助10
13秒前
小桔灯发布了新的文献求助10
13秒前
一阳完成签到,获得积分0
13秒前
泰想成功完成签到,获得积分10
13秒前
whale完成签到,获得积分10
13秒前
吕半鬼完成签到,获得积分0
14秒前
整齐的飞兰完成签到 ,获得积分10
15秒前
Ec关闭了Ec文献求助
15秒前
15秒前
16秒前
美好海瑶完成签到,获得积分10
17秒前
小芳儿完成签到,获得积分10
17秒前
18秒前
健忘碧菡完成签到,获得积分10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Molecular Biology of Cancer: Mechanisms, Targets, and Therapeutics 3000
Kinesiophobia : a new view of chronic pain behavior 3000
Les Mantodea de guyane 2500
Feldspar inclusion dating of ceramics and burnt stones 1000
What is the Future of Psychotherapy in a Digital Age? 801
The Psychological Quest for Meaning 800
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 计算机科学 有机化学 物理 生物化学 纳米技术 复合材料 内科学 化学工程 人工智能 催化作用 遗传学 数学 基因 量子力学 物理化学
热门帖子
关注 科研通微信公众号,转发送积分 5960868
求助须知:如何正确求助?哪些是违规求助? 7211982
关于积分的说明 15957409
捐赠科研通 5097286
什么是DOI,文献DOI怎么找? 2738884
邀请新用户注册赠送积分活动 1701110
关于科研通互助平台的介绍 1618983